Goldman Sachs analyst Patrick Donnelly added Exact Sciences to the firm’s Americas Conviction List, citing his view that the stock is set-up well for the remainder of 2019. Cologuard is a unique growth story, competing liquid biopsy products are likely years away from commercial launches and optionality from pipeline products is currently underappreciated, Donnelly tells investors. He keeps a $120 price target on Exact Sciences shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.